Search Results
14 protocol(s) meet the specified criteria
102756Open  
Testing the Addition of the Oral Medication Ibrutinib to Autologous Stem Cell Transplantation for Patients with Relapsed Diffuse Large B-Cell Lymphoma

102932Open  
Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)

103123Open  
Multicenter, Phase I, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced Malignancies

103706Open  
Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects with Relapsed or Refractory Hematologic Malignancies

105515Open  
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

105847Open  
Master Protocol for Biomarker-Based Treatment of AML (Beat AML Trial)

107742Open  
Phase II Study of Onalespib in ALK+ ALCL, MCL, and BCL-6+ DLBCL

76853Open  
Phase I/IB Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies

85518Open  
Dose-Escalation Study of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export, and Ibrutinib, a Bruton Tyrosine Kinase Inhibitor, in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

87238Open  
Phase I/II Study of Intratumoral G100 Therapy in Patients with Follicular Non-Hodgkin Lymphoma

87799Open  
Phase I Dose-Ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 following Local Intratumoral and Subcutaneous Injection in Patients with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Sub-Type

89837Open  
Phase I, Open-Label, Dose-Escalation Study of SGN-CD19B in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

90576Open  
Phase I, Open-Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients with Advanced/Metastatic Solid Tumors or Lymphomas

99122Open  
Phase II, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement